Difference between prostate and bowel cancer

The present invention furthermore relates to a process for the preparation of the above-mentioned composition, the therapeutic uses thereof, and pharmaceutical compositions containing the nanocomposition according to the invention.

It is an anthracycline antibiotic, closely related to the natural product daunomycin, and like all anthracyclines, it works by intercalating DNA, with the most serious adverse effect being life-threatening heart damage.

It is commonly used in the treatment of a wide range of cancers, including hematological malignancies, many types of carcinoma, and soft tissue sarcomas. Doxorubicin interacts with DNA by intercalation and inhibition of macromolecular biosynthesis. This inhibits the progression of the enzyme topoisomerase II, which relaxes supercoils in DNA for transcription. Doxorubicin stabilizes the topoisomerase II complex after it has broken the DNA chain for replication, preventing the DNA double helix from being resealed and thereby stopping the process of replication.

The planar aromatic chromophore portion of the molecule intercalates between two base pairs of the DNA, while the six-membered daunosamine sugar sits in the minor groove and interacts with flanking a prosztatitis előírva pairs immediately adjacent to the intercalation site, as evidenced by several crystal structures.

Acute adverse effects of doxorubicin can include nausea, vomiting, heart arrhythmias and Typhlitis, an acute life-threatening infection of the bowel. It can also cause neutropenia a decrease in white blood cellsas well as complete alopecia hair loss. A more mild side effect is discoloration of the urine, which can turn bright red for up to 48 hours after dosing.

Clinical trials

Doxorubicin cardiotoxicity is characterized by a dose-dependent decline in mitochondrial oxidative phosphorylation. Reactive oxygen species, generated by the interaction of doxorubicin with iron, can then damage the myocytes heart cellscausing myofibrillar loss and cytoplasmic vacuolization.

Additionally, some patients may develop PPE, characterized by skin eruptions on the palms of the hand or soles of the feet, swelling, pain and erythema. As it can be seen above, the adverse effects of doxorubicin cause a limiting factor for the dosing regimen.

1. Introduction

There is an unmet need to find a composition comprising a carrier and targeting system, which delivers the active compound specifically to the tumour cells, thereby reducing the dose needed, and accordingly, the adverse effects on the intact tissues. A number of attempts have been made to find a composition which satisfies the above need. Biomolecules and their modified derivatives form stable complexes with paramagnetic ions thus increasing the molecular relaxivity of carriers. The synthesis of biomolecular based nanodevices for targeted delivery of MRI contrast agents is also described.

Nanoparticles have been constructed by prostate adenocarcinoma of chitosan as polycation and poly-gamma glutamic acids as polyanion. Nanoparticles are capable of Gd-ion uptake forming a particle with suitable molecular relaxivity.

There is no active agent and therapeutic use disclosed in U. The nanoparticles are characterized with a positive surface charge configured for promoting enhanced permeability for bioactive agent delivery.

The pharmaceutical composition consists of a shell portion that is dominated by positively charged chitosan and a core portion, wherein the core portion consists of the positively charged chitosan, a transition metal ion, one negatively charged substrate, at least one bioactive agent loaded within the nanoparticles, and optionally a zero-charge compound.

• ‪Gabor Veres‬ - ‪Google Tudós‬
• American Journal of Cancer Research
• Nincs libidó a prosztatitisben
• Principal inclusion criteria 1.
• Chaga kezelés prosztatitis
• Licorfite prosztatitis
• Extracelluláris vesiculák minden szervezetben képződnek.
• Rák- prosztatitis kezelés

The composition may contain at least difference between prostate and bowel cancer bioactive agent selected from the group of exendin-4, GLP-1, GLP-1 analog, insulin or insulin analog.

Doxorubicin is not mentioned among the possible active agents. WO relates to an implantable device comprising a biocompatible and biodegradable matrix impregnated with a bioactive complex suitable for selectively targeting the lymphatic system, wherein the bioactive complex comprises one or more particle forming materials and among other bioactive agents e.

The implantable device according to the document comprises a biocompatible and biodegradable matrix impregnated with a bioactive complex suitable for selectively targeting the lymphatic system, wherein the bioactive complex comprises one or more particle forming materials and one or more bioactive agents.

The particles are microparticles or nanoparticles or their combination of microparticles and nanoparticles and the particle size is from about 0.

Areas of application

Unlike our invention, there is no targeting agent in the above-mentioned composition, and the specific effect is attempted to be achieved by implantation.

US relates to a method of enhancing intestinal or blood brain paracellular transport configured for delivering at least one bioactive agent in a patient comprising administering nanoparticles composed of [gamma]-PGA and chitosan.

The administration of the nanoparticles takes place orally. The chitosan is a low molecular weight chitosan 50 kDa and dominates on a surface of said nanoparticles. The surface of said nanoparticles is characterized by a positive surface charge.

New Insights into the Biological and Pharmaceutical Properties of Royal Jelly

The nanoparticles have a mean particle size between about 50 and nanometers and are formed via a simple and mild ionic-gelation method. The nanoparticles are loaded with a therapeutically effective amount of at least one bioactive agent.

In the above-mentioned prior art document doxorubicin is not mentioned as possible therapeutically active agent. Furthermore, though the composition may enhance the penetration of the blood brain carrier, targeting of the therapeutics has not been solved by the invention.

WO relates to magnetically targetable particles comprising at least one magnetic component. The particles are capable of delivering selectively to a site or organ a biologically active substance, e.

Understanding Prostate Cancer

The particles are prepared by e. Also described are methods for making the particles, methods for localized in vivo delivery of a biologically active agent utilizing the particles, a kit for the administration of the particles, as well as a method for sterilizing the particles.

The composition disclosed has a different structure from that of our invention, using different components.

Hivatkozások évente

The state of the art failed to solve the above-mentioned problem that is the reduction of the adverse effects of doxorubicin through the decrease of the incorporated active agent by its targeted delivery.

There is an unsatisfied need to provide for a stable composition for the targeted therapeutic treatment of tumours using doxorubicin. We performed systematic research in the field and, as a result of our surprising findings, completed our invention. This figure shows the size distribution of doxorubicin-loaded nanoparticles by intensity in which nanocarriers were constructed by self-assembly of biopolymers at a concentration of 0.

The injected volume contained the same concentration of doxorubicin.

The nanocarrier system according to the present invention consists of at least four components: a polycation, a polyanion, an active agent, which is doxorubicin or its hydrochloride salt, and a targeting molecule, which may be linked to the polycation, the polyanion or both, or to the surface of the nanoparticle. The formation of the nanoparticles takes place by the self assembling of the polyelectrolites.

In a preferred embodiment, the biopolymers are water-soluble, biocompatible, biodegradable polyelectrolyte biopolymers. One of the polyelectrolyte biopolymers is a polycation, positively charged polymers, which is preferably chitosan or any of its derivatives.

Share Link

In a preferred embodiment in the composition according to the invention the polycation is chitosan, or the modified polycation. The other type of the polyelectrolyte biopolymers is a polyanion, a negatively charged biopolymer. The derivatives of biopolymers can be their cross-linked nanosystems, biopolymer-complexone products, or other grafted derivatives resulted in modifications of biopolymers with other molecules, e.

PEG oligomers. In a preferred embodiment, the drug molecules are ionically or covalently attached to the prosztatarákkal meddig lehet élni or its derivatives via their difference between prostate and bowel cancer groups.